Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Previous Page

Next Page

Page Background

Is PFS1 a survival surrogate?

ALTA1L TRIAL

ALEX TRIAL

Brigatinib

vs

. Crizotinib. Brain MRI/8w

Alectinib

vs

. Crizotinib. Brain MRI/8w

Crossover not allowed

(post-crizo treatment NR)

25% crossover

Peters – NEJM 2018 * Camidge – NEJM 2018